01—Abstract
Summary
Summary of the 8-K filed July 6, 2026. Cited figures are marked; the original filing is the authoritative source.
AbbVie Inc. (ABBV) has filed an 8-K detailing preliminary second-quarter 2026 financial expectations, specifically addressing the impact of acquired In-Process Research and Development (IPR&D) and milestones expense.
The company anticipates a pre-tax charge of $291 milliona related to these expenses, which is expected to negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.17 each. While these are preliminary estimates and subject to final financial closing procedures, investors should note this significant expense impacting near-term profitability. Despite the unfavorable impact from acquired IPR&D and milestones, AbbVie has reaffirmed its full-year 2026 adjusted diluted earnings per share guidance, now projected to be between $13.91 and $14.11.
This revised guidance range incorporates the estimated second-quarter expense. The company also provided a specific second-quarter 2026 adjusted diluted earnings per share guidance range of $3.57 to $3.61b, which also includes this expense. Investors are reminded that acquired IPR&D and milestones are inherently unpredictable and are not typically forecasted beyond the initial quarter they are incurred.
02—Key points
Key Highlights
- AbbVie estimates $291 million in pre-tax acquired IPR&D and milestones expense for Q2 2026.
- This expense is expected to reduce both GAAP and adjusted non-GAAP diluted EPS by $0.17 for Q2 2026.
- The company has reaffirmed its full-year 2026 adjusted diluted EPS guidance range of $13.91 - $14.11, now including the Q2 expense.
- AbbVie provides a Q2 2026 adjusted diluted EPS guidance range of $3.57 - $3.61, incorporating the identified expense.
- Acquired IPR&D and milestones expenses are not typically forecasted by AbbVie due to their uncertain timing and occurrence.
- The filing includes guidance as Exhibit 99.1, which details the estimated acquired IPR&D and milestones expense for Q2 2026.
- The company includes standard forward-looking statement disclaimers, outlining risks and uncertainties that could affect actual results.
03—Questions
Frequently Asked Questions
What is the primary reason for the announced financial impact in the 8-K filing?
The primary reason is the estimated $291 million in pre-tax acquired In-Process Research and Development (IPR&D) and milestones expense expected to be incurred during the second quarter of 2026. This expense is anticipated to negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.17 each for the quarter.
Has AbbVie changed its full-year 2026 earnings guidance due to this expense?
No, AbbVie has reaffirmed its full-year 2026 adjusted diluted earnings per share guidance range of $13.91 - $14.11. This range has been updated to include the impact of the estimated second-quarter acquired IPR&D and milestones expense.
What is the expected adjusted diluted EPS for the second quarter of 2026?
AbbVie's guidance for the second quarter of 2026, including the impact of the acquired IPR&D and milestones expense, is a range of $3.57 to $3.61 per diluted share on an adjusted non-GAAP basis.
Why does AbbVie not typically forecast acquired IPR&D and milestones expense?
AbbVie does not forecast acquired IPR&D and milestones expense because these expenses are often incurred upon the execution of collaborations, licensing agreements, and other asset acquisitions, making their future occurrence and timing inherently uncertain and unpredictable.
04—Continue